Vela Diagnostics, Singapore, has acquired the assets of Great Basin Scientific, and will take over the company’s research and development site in Salt Lake City.
Great Basin Scientific has a chip-based analyzer running six FDA-approved, cartridge-based microbiology assays, including tests for Bordetella direct; Clostridiodes difficile; group B Streptococcus; Shiga toxin direct; Staphylococcus ID/R blood culture; and stool bacterial pathogens.
The microbiology assays provide fast, multiple-pathogen diagnoses, and are offered to point-of-care customers, including hospitals and near-patient care providers.
With its acquisition of Great Basin, Vela enters the microbiology market, adding to the current segments of the company in oncology and virology.
“Great Basin’s technology is a strategic fit to the Vela portfolio, as it covers medium-multiplexing solutions and complements both Vela’s low-multiplexing polymerase chain reaction (PCR) and high-multiplexing next-generation sequencing (NGS) platform,” says Michael Tillmann, CEO of Vela Diagnostics. “With the addition of Great Basin’s technology, near-patient care customers will be able to benefit from this new microbiology offering in our existing geographies, and our presence in the US will be enhanced.”
For additional information, visit Vela Diagnostics.